 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Amphastar Pharmaceuticals, Inc. (AMPH) focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products.
It operates in two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.
The companys product portfolio comprises Enoxaparin, a low molecular weight heparin that is used as an anticoagulant for prevention and treatment of deep vein thrombosis; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients presumed with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection for the dispersion and absorption of other injected drugs; and Lidocaine jelly, a local anesthetic product used primarily for urological procedures.
It also provides Lidocaine topical solution, a local anesthetic for various procedures; phytonadione injection for newborn babies; syringe products, which include critical care drugs, such as morphine, atropine, calcium chloride, dextrose, lidocaine, naloxone, and sodium bicarbonate for emergency use in hospital settings; and epinephrine in vial form; and lorazepam injection, a sedative for surgery and medical procedures.
In addition, the company develops Primatene Mist HFA, an over-the-counter epinephrine inhalation product candidate that is intended to be used for the temporary relief of mild symptoms of intermittent asthma; and active pharmaceutical ingredients, such as recombinant human insulin and porcine insulin. Further, it has a pipeline of 21 generic and proprietary product candidates in various stages of development for various indications. The companys products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers.
Shares have formed a bullish "flag" following its recent earnings report. On a per-share basis, the company said it had profit of 8 cents. Earnings, adjusted for stock option expense and non-recurring costs, were 14 cents per share. Estimates called for 2 cents. The company posted revenue of $64.2 million in the period. Higher share prices are expected for this stock.
52-Weeks Trading Range: $10.50 - $21.53
Entry Point: $20.75
Stop Loss: $19.71
Target Price: $22.82
AMPH closed at $20.43
